Cargando…

MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy

SIMPLE SUMMARY: The Melanoma Antigen Gene (MAGE) protein family is a large group of proteins that share a common MAGE homology domain. Many MAGE proteins are aberrantly expressed in a wide variety of cancer types and are of interest as a biomarkers in cancer and targets of immunotherapies because of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lisica Šikić, Nataša, Petrić Miše, Branka, Tomić, Snježana, Spagnol, Giulia, Matak, Luka, Juretić, Antonio, Spagnoli, Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571787/ https://www.ncbi.nlm.nih.gov/pubmed/37835391 http://dx.doi.org/10.3390/cancers15194697

Ejemplares similares

Rectal prolapse as the initial presentation of rectal cancer—A case report
por: Jurić, Oliver, et al.
Publicado: (2023)

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas
por: Sundov, Dinka, et al.
Publicado: (2013)

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
por: Matković, Božica, et al.
Publicado: (2011)

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
por: Hudolin, Tvrtko, et al.
Publicado: (2013)

MAGE-A Antigens and Cancer Immunotherapy
por: Zajac, Paul, et al.
Publicado: (2017)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
por: Čeprnja, Toni, et al.
Publicado: (2022)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
por: Reyes-Gonzalez, Jeyshka M., et al.
Publicado: (2019)

AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer
por: Hojnik, Marko, et al.
Publicado: (2022)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

COVID‐19 Pandemic Effects on Breast Cancer Diagnosis in Croatia: A Population‐ and Registry‐Based Study
por: Vrdoljak, Eduard, et al.
Publicado: (2021)

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
por: Majić, Ana, et al.
Publicado: (2020)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
por: Weberpals, Johanne I., et al.
Publicado: (2021)

Characteristics of Extracellular Vesicles from a High-Grade Serous Ovarian Cancer Cell Line Derived from a Platinum-Resistant Patient as a Potential Tool for Aiding the Prediction of Responses to Chemotherapy
por: Černe, Katarina, et al.
Publicado: (2023)

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
por: Liu, Yixin, et al.
Publicado: (2019)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer
por: Wang, Wei, et al.
Publicado: (2019)

RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
por: Kim, Kyeongmin, et al.
Publicado: (2023)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
por: Silva, Vera L., et al.
Publicado: (2021)

Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells
por: Poschner, Stefan, et al.
Publicado: (2020)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
por: Reid, Brett M., et al.
Publicado: (2021)

Pathogenicity of the MAGE family
por: Li, Sanyan, et al.
Publicado: (2021)

In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
por: Junwei, Wang, et al.
Publicado: (2016)

Expression of MAGE-1 and -3 genes and gene products in human hepatocellular carcinoma
por: Kariyama, K, et al.
Publicado: (1999)

Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study
por: Liu, Rong, et al.
Publicado: (2020)

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
por: Daudi, Sayeema, et al.
Publicado: (2014)

Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer
por: Vanguri, Rami, et al.
Publicado: (2022)

The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma
por: Shen, Yuanming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_009j7vk1i5eq31qh1cqpci3ief